指南与共识消化、代谢与肾脏急症复苏、休克与脓毒症

AGA临床实践更新:肝硬化中血管活性药物与静脉白蛋白的使用专家综述

AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
指南 / 共识 · Gastroenterology · 2023-11-18
一句话结论AGA专家建议:怀疑或确诊食管胃静脉曲张出血即启动血管活性药物(首选奥曲肽),大容量(>5 L)放腹水时用静脉白蛋白,特利加压素治疗HRS-AKI且不需ICU监测。

该专家综述由美国胃肠病学协会(AGA)研究所临床实践更新委员会和AGA理事会委托并批准,基于已发表文献回顾和专家意见,针对肝硬化患者提出12条最佳实践建议,涵盖静脉曲张出血、腹水与自发性细菌性腹膜炎(SBP)、肝肾综合征(HRS-AKI)三个场景。建议指出:怀疑或确诊静脉曲张出血即启动血管活性药物,最好在内镜前;内镜止血后继续用药2-5天;奥曲肽因安全性好为首选;大容量(>5 L)放腹水时给予静脉白蛋白;SBP患者可考虑静脉白蛋白;无并发症腹水不用白蛋白和血管收缩剂;HRS-AKI首选特利加压素,可考虑联用白蛋白,不需ICU监测,可经外周静脉给药。

要点

  • 怀疑或确诊静脉曲张出血即启动血管活性药物,最好在诊断和治疗性内镜前(建议1)。
  • 内镜初始止血后血管活性药物继续2-5天以预防早期再出血(建议2)。
  • 奥曲肽因安全性是静脉曲张出血的首选血管活性药物(建议3)。
  • 大容量(>5 L)放腹水时给予静脉白蛋白;SBP患者可考虑静脉白蛋白(建议4、5)。
  • HRS-AKI首选特利加压素,不需ICU监测,可经外周静脉给药;低氧血症及持续冠脉、外周或肠系膜缺血者禁用(建议10-12)。

适用人群与场景

  • 肝硬化患者,涵盖代偿期、失代偿期和进一步失代偿期,中位生存期分别超过15年、2年和9个月。
  • 静脉曲张出血、腹水(包括无并发症腹水、大容量放腹水、SBP)以及HRS-AKI患者。

诊断标准与关键阈值

  • 肝硬化分期:代偿期、失代偿期、进一步失代偿期。
  • 大容量放腹水定义为>5 L。
  • HRS-AKI为肝硬化最致命的并发症。
  • 特利加压素禁忌:低氧血症、持续冠脉/外周/肠系膜缺血;慢加急性肝衰竭3级慎用;血清肌酐>5 mg/dL及等待移植且MELD≥35者获益可能不抵风险。

处置流程与药物剂量

  • 怀疑或确诊静脉曲张出血即启动血管活性药物,最好在诊断和/或治疗性内镜前(建议1)。
  • 内镜初始止血后血管活性药物继续2-5天以预防早期再出血(建议2)。
  • 静脉曲张出血首选奥曲肽(建议3)。
  • 大容量(>5 L)放腹水时给予静脉白蛋白(建议4)。
  • SBP患者可考虑静脉白蛋白(建议5)。
  • 住院肝硬化腹水合并AKI患者,静脉白蛋白为首选扩容剂(建议8)。
  • HRS-AKI使用血管活性药物(如特利加压素、去甲肾上腺素、奥曲肽联合米多君),不用于其他类型AKI(建议9)。
  • HRS-AKI首选特利加压素,可考虑联用白蛋白并评估容量状态;特利加压素不需ICU监测,可经外周静脉给药(建议10、11)。

红旗征与不能漏的情况

  • 低氧血症患者禁用特利加压素(建议12)。
  • 持续冠脉、外周或肠系膜缺血患者禁用特利加压素(建议12)。
  • 慢加急性肝衰竭3级患者慎用特利加压素(建议12)。
  • 血清肌酐>5 mg/dL及等待移植且MELD≥35者,特利加压素获益可能不抵风险(建议12)。
  • 无并发症腹水患者(住院或非住院)不应使用白蛋白(建议6)。
  • 无并发症腹水、大容量放腹水后或SBP患者不应使用血管收缩剂(建议7)。

研究设计与关键结果

  • 该专家综述由AGA研究所临床实践更新委员会和AGA理事会委托并批准,经Gastroenterology标准内部同行评议。
  • 建议来自已发表文献回顾和专家意见,部分建议因缺乏新证据与已发表指南相同。
  • 未进行系统评价,因此最佳实践建议未对证据质量或推荐强度进行正式评级。

证据类型、等级与局限

  • 证据类型:专家综述(最佳实践建议),基于文献回顾和专家意见,未进行系统评价,无正式证据质量或推荐强度评级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 静脉曲张出血应在怀疑或确诊时即启动血管活性药物,最好在内镜前,内镜止血后继续2-5天;奥曲肽因安全性为首选。
  • 大容量(>5 L)放腹水时给予静脉白蛋白;SBP患者可考虑静脉白蛋白;无并发症腹水不用白蛋白和血管收缩剂。
  • 住院肝硬化腹水合并AKI时,静脉白蛋白为首选扩容剂。
  • HRS-AKI使用血管活性药物(如特利加压素、去甲肾上腺素、奥曲肽联合米多君),不用于其他类型AKI;首选特利加压素,可考虑联用白蛋白并评估容量状态;特利加压素不需ICU监测,可经外周静脉给药。
  • 特利加压素禁用于低氧血症及持续冠脉、外周或肠系膜缺血者,慢加急性肝衰竭3级慎用,血清肌酐>5 mg/dL及等待移植且MELD≥35者获益可能不抵风险。

指南或共识出处

  • AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review(Gastroenterology)
  • 美国胃肠病学协会(AGA)研究所临床实践更新委员会和AGA理事会

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

DESCRIPTION: Cirrhosis is a major cause of morbidity and mortality in the United States and worldwide. It consists of compensated, decompensated, and further decompensated stages; median survival is more than 15 years, 2 years, and 9 months for each stage, respectively. With each stage, there is progressive worsening of portal hypertension and the vasodilatory-hyperdynamic circulatory state, resulting in a progressive decrease in effective arterial blood volume and renal perfusion. Vasoconstrictors reduce portal pressure via splanchnic vasoconstriction and are used in the management of variceal hemorrhage. Intravenous (IV) albumin increases effective arterial blood volume and is used in the prevention of acute kidney injury (AKI) and death after large-volume paracentesis and in patients with spontaneous bacterial peritonitis (SBP). The combination of vasoconstrictors and albumin is used in the reversal of hepatorenal syndrome (HRS-AKI), the most lethal complication of cirrhosis. Because a potent vasoconstrictor, terlipressin, was recently approved by the US Food and Drug Administration, and because recent trials have explored use of IV albumin in other settings, it was considered that a best practice update would be relevant regarding the use of vasoactive drugs and IV albumin in the following 3 specific scenarios: variceal hemorrhage, ascites and SBP, and HRS.

METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership. It underwent internal peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Some of the statements are unchanged from published guidelines because of lack of new evidence in the literature. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality and evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: Vasoactive drugs should be initiated as soon as the diagnosis of variceal hemorrhage is suspected or confirmed, preferably before diagnostic and/or therapeutic endoscopy. BEST PRACTICE ADVICE 2: After initial endoscopic hemostasis, vasoactive drugs should be continued for 2-5 days to prevent early rebleeding. BEST PRACTICE ADVICE 3: Octreotide is the vasoactive drug of choice in the management of variceal hemorrhage based on its safety profile. BEST PRACTICE ADVICE 4: IV albumin should be administered at the time of large-volume (>5 L) paracentesis. BEST PRACTICE ADVICE 5: IV albumin may be considered in patients with SBP. BEST PRACTICE ADVICE 6: Albumin should not be used in patients (hospitalized or not) with cirrhosis and uncomplicated ascites. BEST PRACTICE ADVICE 7: Vasoconstrictors should not be used in the management of uncomplicated ascites, after large-volume paracentesis or in patients with SBP. BEST PRACTICE ADVICE 8: IV albumin is the volume expander of choice in hospitalized patients with cirrhosis and ascites presenting with AKI. BEST PRACTICE ADVICE 9: Vasoactive drugs (eg, terlipressin, norepinephrine, and combination of octreotide and midodrine) should be used in the treatment of HRS-AKI, but not in other forms of AKI in cirrhosis. BEST PRACTICE ADVICE 10: Terlipressin is the vasoactive drug of choice in the treatment of HRS-AKI and use of concurrent albumin can be considered when accounting for patient's volume status. BEST PRACTICE ADVICE 11: Terlipressin treatment does not require intensive care unit monitoring and can be administered intravenously through a peripheral line. BEST PRACTICE ADVICE 12: Terlipressin use is contraindicated in patients with hypoxemia and in patients with ongoing coronary, peripheral, or mesenteric ischemia, and should be used with caution in patients with acute-on-chronic liver failure grade 3. The benefits may not outweigh the risks in patients with serum creatinine >5 mg/dL and in patients listed for transplantation with a Model for End-stage Liver Disease ≥35.

来源:Gastroenterology,查看原文。版权归原作者所有。

参考来源

  1. Garcia-Tsao G, Abraldes JG, Rich NE, et al. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology. 2023. PMID: 37978969. doi:10.1053/j.gastro.2023.10.016

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。